[Ulcerative Colitis-associated Carcinogenesis : An Update]

Overview

Journal Pathologie (Heidelb)

Specialty Pathology

Date 2023 Jun 13

PMID 37311872

Authors

Daniela E Aust

Gustavo B Baretton

Ulrich Sommer

Affiliations

Soon will be listed here.

Abstract

Ulcerative colitis (UC) is a chronic inflammatory bowel disease beginning in the rectum and gradually extending to the right-sided colon and the terminal ileum (backwash-ileitis). Its causes are still not completely understood. Genetic susceptibility, changes in the microbiota and immune response, as well as environmental factors are thought to influence the disease course.Patients with UC are at increased risk of developing colorectal cancer (CRC) when compared to an age-matched normal population. Cancer risk increases with early onset, duration, and extent of the disease, with development of strictures, intraepithelial neoplasia, and concomitant primary sclerosing cholangitis.In contrast to the sporadic adenoma-carcinoma-sequence, UC-related CRC develops through an inflammation-intraepithelial neoplasia-carcinoma-sequence, in which genetic alterations already occur in the inflamed epithelium before the development of intraepithelial neoplasia.This article summarizes the current state of knowledge regarding UC-related carcinogenesis and its possible impact on prevention and therapy.

References

Andre T, Shiu K, Kim T, Jensen B, Jensen L, Punt C . Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. N Engl J Med. 2020; 383(23):2207-2218. DOI: 10.1056/NEJMoa2017699. View

Aust D, Baretton G, Waldman F, Lohrs U . [Molecular carcinogenesis in ulcerative colitis-associated and sporadic colorectal carcinoma--differences and similarities]. Verh Dtsch Ges Pathol. 2000; 83:130-8. View

Aust D, Terdiman J, Willenbucher R, Chang C, Baretton G, Loehrs U . The APC/beta-catenin pathway in ulcerative colitis-related colorectal carcinomas: a mutational analysis. Cancer. 2002; 94(5):1421-7. DOI: 10.1002/cncr.10334. View

Bajpai M, Seril D, Van Gurp J, Geng X, Alvarez J, Minacapelli C . Effect of Long-Term Mesalamine Therapy on Cancer-Associated Gene Expression in Colonic Mucosa of Patients with Ulcerative Colitis. Dig Dis Sci. 2018; 64(3):740-750. DOI: 10.1007/s10620-018-5378-8. View

Beaugerie L, Itzkowitz S . Cancers complicating inflammatory bowel disease. N Engl J Med. 2015; 372(15):1441-52. DOI: 10.1056/NEJMra1403718. View

Biarc J, Nguyen I, Pini A, Gosse F, Richert S, Thierse D . Carcinogenic properties of proteins with pro-inflammatory activity from Streptococcus infantarius (formerly S.bovis). Carcinogenesis. 2004; 25(8):1477-84. DOI: 10.1093/carcin/bgh091. View

Carrat F, Seksik P, Colombel J, Peyrin-Biroulet L, Beaugerie L . The effects of aminosalicylates or thiopurines on the risk of colorectal cancer in inflammatory bowel disease. Aliment Pharmacol Ther. 2016; 45(4):533-541. DOI: 10.1111/apt.13897. View

Chen D, Irving B, Hodi F . Molecular pathways: next-generation immunotherapy--inhibiting programmed death-ligand 1 and programmed death-1. Clin Cancer Res. 2012; 18(24):6580-7. DOI: 10.1158/1078-0432.CCR-12-1362. View

Chen D, Mellman I . Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013; 39(1):1-10. DOI: 10.1016/j.immuni.2013.07.012. View

10.

Fan X, Jin Y, Chen G, Ma X, Zhang L . Gut Microbiota Dysbiosis Drives the Development of Colorectal Cancer. Digestion. 2020; 102(4):508-515. DOI: 10.1159/000508328. View

11.

Fleisher A, Esteller M, Harpaz N, Leytin A, Rashid A, Xu Y . Microsatellite instability in inflammatory bowel disease-associated neoplastic lesions is associated with hypermethylation and diminished expression of the DNA mismatch repair gene, hMLH1. Cancer Res. 2000; 60(17):4864-8. View

12.

Gao J, Shi L, Zhao H, Chen J, Xiong L, He Q . Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy. Cell. 2016; 167(2):397-404.e9. PMC: 5088716. DOI: 10.1016/j.cell.2016.08.069. View

13.

Gordillo J, Cabre E, Garcia-Planella E, Ricart E, Ber-Nieto Y, Marquez L . Thiopurine Therapy Reduces the Incidence of Colorectal Neoplasia in Patients with Ulcerative Colitis. Data from the ENEIDA Registry. J Crohns Colitis. 2015; 9(12):1063-70. DOI: 10.1093/ecco-jcc/jjv145. View

14.

Hartnett L, Egan L . Inflammation, DNA methylation and colitis-associated cancer. Carcinogenesis. 2012; 33(4):723-31. DOI: 10.1093/carcin/bgs006. View

15.

Li W, Zhao T, Wu D, Li J, Wang M, Sun Y . Colorectal Cancer in Ulcerative Colitis: Mechanisms, Surveillance and Chemoprevention. Curr Oncol. 2022; 29(9):6091-6114. PMC: 9498229. DOI: 10.3390/curroncol29090479. View

16.

Lizardo D, Kuang C, Hao S, Yu J, Huang Y, Zhang L . Immunotherapy efficacy on mismatch repair-deficient colorectal cancer: From bench to bedside. Biochim Biophys Acta Rev Cancer. 2020; 1874(2):188447. PMC: 7886024. DOI: 10.1016/j.bbcan.2020.188447. View

17.

Lu Y, Li X, Liu S, Zhang Y, Zhang D . Toll-like Receptors and Inflammatory Bowel Disease. Front Immunol. 2018; 9:72. PMC: 5797585. DOI: 10.3389/fimmu.2018.00072. View

18.

Lucafo M, Curci D, Franzin M, Decorti G, Stocco G . Inflammatory Bowel Disease and Risk of Colorectal Cancer: An Overview From Pathophysiology to Pharmacological Prevention. Front Pharmacol. 2021; 12:772101. PMC: 8563785. DOI: 10.3389/fphar.2021.772101. View

19.

Ozawa N, Yokobori T, Osone K, Katayama C, Suga K, Komine C . PD-L1 upregulation is associated with activation of the DNA double-strand break repair pathway in patients with colitic cancer. Sci Rep. 2021; 11(1):13077. PMC: 8219733. DOI: 10.1038/s41598-021-92530-3. View

20.

Parada Venegas D, De la Fuente M, Landskron G, Gonzalez M, Quera R, Dijkstra G . Short Chain Fatty Acids (SCFAs)-Mediated Gut Epithelial and Immune Regulation and Its Relevance for Inflammatory Bowel Diseases. Front Immunol. 2019; 10:277. PMC: 6421268. DOI: 10.3389/fimmu.2019.00277. View